Please enable JS

Investors & Media

2017 News Releases

Webcast ImageWebcast
CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents (Replay)
02/16/17 at 11:00 a.m. ET
CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents
Thursday, February 16, 2017 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
Feb-15-2017CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents
BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that management will host a conference call and live audio webcast on Thursday, February 16, 2017 at 11:00 a.m. ET to provide an update on the CRISPR/Cas9 U.S. Patent Interference Proceedings as well as an update on the corresponding U.K. patents.    ... 
Printer Friendly Version
Feb-15-2017CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuance Additional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual... 
Printer Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet